Key result
Administration of globular adiponectin reduced infarct size and cardiomyocyte apoptosis in 7-week T1DM mice, but failed to attenuate myocardial ischemia/reperfusion injury in 1-week T1DM mice.
Why the study?
Does administration of globular adiponectin or an AMPK activator reduce myocardial ischemia/reperfusion injury in type 1 diabetic mice?
Does administration of globular adiponectin or an AMPK activator reduce myocardial ischemia/reperfusion injury in type 1 diabetic mice?
The study demonstrates a dynamic dysfunction of the adiponectin/AdipoR1 axis during T1DM progression, suggesting that timing of adiponectin supplementation or AdipoR1 modulation is critical for reducing myocardial ischemic injury.
Supports timing-dependent adiponectin effects in T1DM models; leaves open whether AdipoR1 modulation protects early diabetic hearts from I/R injury.
The present study determined the dynamic change of adiponectin (APN, a cardioprotective adipokine), its receptor expression, and their impact upon myocardial ischemia/reperfusion (MI/R) injury during type 1 diabetes mellitus (T1DM) progression, and involved underlying mechanisms. Diabetic state was induced in mice via multiple intraperitoneal injections of low-dose streptozotocin. The dynamic change of plasma APN concentration and cardiac APN receptor-1 and -2 (AdipoR1/2) expression were assessed immediately after diabetes onset (0 wk) and 1, 3, 5, and 7 wk thereafter. Indicators of MI/R injury (infarct size, apoptosis, and LDH release) were determined at 0, 1, and 7 wk of DM duration. The effect of APN on MI/R injury was determined in mice subjected to different diabetic durations. Plasma APN levels (total and HMW form) increased, whereas cardiac AdipoR1 expression decreased early after T1DM onset. With T1DM progression, APN levels were reduced and cardiac AdipoR1 expression increased. MI/R injury was exacerbated with T1DM progression in a time-dependent manner. Administration of globular APN (gAD) failed to attenuate MI/R injury in 1-wk T1DM mice, while an AMP-activated protein kinase (AMPK) activator (AICAR) reduced MI/R injury. However, administration of gAD (and AICAR) reduced infarct size and cardiomyocyte apoptosis in 7-wk T1DM mice. In conclusion, our results demonstrate a dynamic dysfunction of APN/AdipoR1 during T1DM progression. Reduced cardiac AdipoR1 expression and APN concentration may be responsible for increased I/R injury susceptibility at early and late T1DM stages, respectively. Interventions bolstering AdipoR1 expression during early T1DM stages and APN supplementation during advanced T1DM stages may potentially reduce the myocardial ischemic injury in diabetic patients.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2011) studied Type 1 diabetes mellitus and myocardial ischemia/reperfusion injury. Globular adiponectin (gAD) or AMPK activator (AICAR) vs. Untreated T1DM mice was evaluated on Myocardial ischemia/reperfusion injury (infarct size, apoptosis, and LDH release). Administration of globular adiponectin reduced infarct size and cardiomyocyte apoptosis in 7-week T1DM mice, but failed to attenuate myocardial ischemia/reperfusion injury in 1-week T1DM mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: